Renal Cell Carcinoma (IMmotion150 Clinical Trial, Nat Med. 2018) - iAtlas Harmonized

Summary

Renal Cell Carcinoma (IMmotion150 Clinical Trial, Nat Med. 2018) - iAtlas Harmonized is a study catalogued by cBioPortal DataHub under the cancer-type code rcc. EvidenceHelix groups it with kidney and bladder studies.

Study description

A randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 263 patients with treatment-naive metastatic renal cell carcinoma. The reprocessing of raw sequencing data is coordinated by CRI iAtlas (https://cri-iatlas.org/).

Text as published in the source's study metadata.

Citation & PubMed

McDermott et al. Nat Med 2018

Linked PubMed records: PMID 29867230

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

rcc_iatlas_immotion150_2018

Short name

not given

Source cancer-type code

rcc

Reference genome

hg38

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

McDermott et al. Nat Med 2018

• PubMed record 29867230 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Metastatic Renal Clear Cell Carcinoma (Phase 1 Biomarker Trial, Clin Cancer Res. 2016) - iAtlas Harmonized

  Whole-exome sequencing and neoantigen landscape analysis of 16 metastatic renal cell carcinomas and their matched normals from an open-label, parallel, four-group, phase 1b study (https://clinicaltrials.gov/study/NCT0…

  Kidney and bladderOther published and consortium studiesSource code rccPubMed 1

• Bladder Urothelial Carcinoma (BGI, Nat Genet 2013)

  Whole-exome and whole-genome sequencing of 99 bladder cancer tumor/normal pairs. Generated by BGI.

  Kidney and bladderOther published and consortium studiesSource code blcaPubMed 1

• Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)

  Whole-exome sequencing of metastatic clear cell renal carcinoma (ccRCC) from 35 tumor/normal pairs.

  Kidney and bladderOther published and consortium studiesSource code ccrccPubMed 1

• Kidney Renal Clear Cell Carcinoma (BGI, Nat Genet 2012)

  Whole-exome sequencing of 10 ccRCC tumor/normal pairs and targeted sequencing of 88 clear cell carcinoma tumor/normal pairs. Generated by BGI-Shenzhen.

  Kidney and bladderOther published and consortium studiesSource code ccrccPubMed 1

• Kidney Renal Clear Cell Carcinoma (IRC, Nat Genet 2014)

  Multi region exome sequencing of 10 clear cell renal cell carcinomas (ccRCCs)

  Kidney and bladderOther published and consortium studiesSource code ccrccPubMed 1

• Metastatic Bladder Urothelial Carcinoma (IMvigor210 Phase II Trial, ESMO Open. 2024) - iAtlas Harmonized

  Whole-exome sequencing and neoantigen landscape analysis of 347 metastatic bladder urothelial carcinomas and their matched normals, generated from a phase II trial of atezolizumab monotherapy in cisplatin-ineligible a…

  Kidney and bladderOther published and consortium studiesSource code blcaPubMed 2

• Renal Cell Carcinoma (St. James, Clin Cancer Res 2023)

  Targeted sequencing of 943 renal clear cell carcinoma samples and their matched normals.

  Kidney and bladderOther published and consortium studiesSource code ccrccPubMed 1

• Renal Clear Cell Carcinoma (UTokyo, Nat Genet 2013)

  Whole exome and/or whole genome sequencing of 106 clear cell renal cell carcinoma tumor/normal pairs.

  Kidney and bladderOther published and consortium studiesSource code ccrccPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.